<p>uniQure（纳斯达克股票代码：QURE - 获取免费报告）在周四的交易中下跌了 4.2%。该公司的股价最低曾达到 12.99 美元，最后交易价为 13.08 美元。在午盘交易中，共成交 453,645 股，较平均交易量 1,015,442 股下降了 55%。该股票此前收盘价为 13.65 美元。</p>
<h2>华尔街分析师观点</h2>
<p>多位股票分析师最近对 QURE 股票发布了报告。StockNews.com 在 3 月 11 日的研究报告中将 uniQure 的评级上调至 “卖出”。Guggenheim 在 12 月 11 日的研究报告中重申了对 uniQure 股票的 “买入” 评级。加拿大皇家银行在 1 月 21 日的研究报告中重申了 “跑赢大盘” 评级，并对 uniQure 股票设定了 24.00 美元的目标价。Raymond James 在 12 月 10 日的研究报告中将 uniQure 的评级从 “跑赢大盘” 上调至 “强力买入”，并将其目标价从 20.00 美元提高至 52.00 美元。最后，高盛集团在 12 月 12 日的研究报告中将 uniQure 的目标价从 9.00 美元提高至 20.00 美元，并给予该股票 “中性” 评级。一位研究分析师对该股票给予了卖出评级，三位给予了持有评级，六位给予了买入评级，还有一位给予了强力买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 38.89 美元。</p>
<p><strong>获取我们对 uniQure 的最新股票分析</strong></p>
<h2>uniQure 价格表现</h2>
<p>该公司的债务与股本比率为 0.92，速动比率为 6.51，流动比率为 6.51。该公司的市值为 6.732 亿美元，市盈率为-2.50，贝塔值为 0.36。该公司的 50 日移动平均线为 13.82 美元，200 日移动平均线为 10.69 美元。</p>
<h2>uniQure 的内部买卖</h2>
<p>在其他消息中，首席执行官 Matthew C. Kapusta 在 3 月 4 日的交易中出售了 28,341 股公司的股票。该股票以平均价格 10.29 美元出售，总交易额为 291,628.89 美元。出售后，首席执行官现在直接持有 651,454 股公司的股票，价值为 6,703,461.66 美元。这代表其持股减少了 4.17%。该交易在向证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，首席财务官 Christian Klemt 在 2 月 27 日的交易中出售了 2,916 股公司的股票。该股票以平均价格 11.32 美元出售，总交易额为 33,009.12 美元。交易完成后，首席财务官现在直接持有 155,168 股公司的股票，价值约为 1,756,501.76 美元。此交易代表其持股减少了 1.84%。该交易的披露信息可在此找到。在过去三个月中，内部人士共出售了 90,830 股公司股票，价值为 961,401 美元。当前 4.74% 的股票由公司内部人士持有。</p>
<h2>对 uniQure 的对冲基金观点</h2>
<p>机构投资者最近买入和卖出了该公司的股票。Avoro Capital Advisors LLC 在第四季度购买了 uniQure 的新头寸，价值为 38,410,000 美元。Franklin Resources Inc.在第四季度将其在 uniQure 的持股增加了 33.1%。Franklin Resources Inc.现在持有 1,987,688 股生物技术公司的股票，价值为 35,103,000 美元，此前在上个季度又购买了 494,726 股。Point72 Asset Management L.P.在第四季度将其在 uniQure 的持股增加了 81.3%。Point72 Asset Management L.P.现在持有 1,771,352 股生物技术公司的股票，价值为 31,282,000 美元，此前在该期间又购买了 794,459 股。Integral Health Asset Management LLC 在第四季度将其在 uniQure 的持股增加了 175.0%。Integral Health Asset Management LLC 现在持有 1,100,000 股生物技术公司的股票，价值为 19,426,000 美元，此前在上个季度又购买了 700,000 股。最后，RTW Investments LP 在第四季度将其在 uniQure 的持股增加了 8,936.3%。RTW Investments LP 现在持有 903,625 股生物技术公司的股票，价值为 15,958,000 美元，此前在该期间又购买了 893,625 股。机构投资者持有该公司 78.83% 的股票。</p>
<h2>uniQure 公司简介</h2>
<p>（获取免费报告）</p>
<p>uniQure N.V.为患有罕见和其他严重疾病的患者开发治疗方案。它提供的 HEMGENIX 已完成针对 B 型血友病的 III 期 HOPE-B 关键试验。该公司还开发了 AMT-130，这是一种正在进行 I/II 期临床研究的基因治疗，用于治疗亨廷顿舞蹈症。</p>
<h2>推荐阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 uniQure</li>
<li>如何投资 FAANG 股票</li>
<li>便士股票激增，SurgePays 上涨 70%：买入的一个理由，卖出的五个理由</li>
<li>什么是欧元 STOXX 50 指数？</li>
<li>三大饮料股票带来丰厚利润</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>CarMax 和 Carvana：引领二手车市场</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 uniQure 吗？</h2>
<p>在你考虑 uniQure 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而 uniQure 并不在名单上。</p>
<p>虽然 uniQure 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

QURE

<p>uniQure（纳斯达克股票代码：QURE）股价下跌 4.2%，至 13.08 美元，交易量较平均水平下降 55%。分析师的评级意见不一，其中一位为卖出，三位为持有，六位为买入，一位为强烈买入。平均评级为 “适度买入”，目标价为 38.89 美元。最近的内部交易包括首席执行官 Matthew C. Kapusta 出售 28,341 股。机构投资者持有该股票的 78.83%，并在上个季度进行了大量购买。uniQure 专注于罕见疾病的治疗，包括 B 型血友病和亨廷顿舞蹈症</p>

<p>Shares of uniQure (NASDAQ:QURE - Get Free Report) traded down 4.2% during trading on Thursday . The company traded as low as $12.99 and last traded at $13.08. 453,645 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 1,015,442 shares. The stock had previously closed at $13.65.</p>
<div class="lb-trans"><p>uniQure（纳斯达克股票代码：QURE - 获取免费报告）在周四的交易中下跌了 4.2%。该公司的股价最低曾达到 12.99 美元，最后交易价为 13.08 美元。在午盘交易中，共成交 453,645 股，较平均交易量 1,015,442 股下降了 55%。该股票此前收盘价为 13.65 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities analysts have recently issued reports on QURE shares. StockNews.com upgraded uniQure to a &#34;sell&#34; rating in a research note on Tuesday, March 11th. Guggenheim reaffirmed a &#34;buy&#34; rating on shares of uniQure in a research report on Wednesday, December 11th. Royal Bank of Canada reiterated an &#34;outperform&#34; rating and issued a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Raymond James upgraded shares of uniQure from an &#34;outperform&#34; rating to a &#34;strong-buy&#34; rating and boosted their target price for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th. Finally, The Goldman Sachs Group increased their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $38.89.</p>
<div class="lb-trans"><p>多位股票分析师最近对 QURE 股票发布了报告。StockNews.com 在 3 月 11 日的研究报告中将 uniQure 的评级上调至 “卖出”。Guggenheim 在 12 月 11 日的研究报告中重申了对 uniQure 股票的 “买入” 评级。加拿大皇家银行在 1 月 21 日的研究报告中重申了 “跑赢大盘” 评级，并对 uniQure 股票设定了 24.00 美元的目标价。Raymond James 在 12 月 10 日的研究报告中将 uniQure 的评级从 “跑赢大盘” 上调至 “强力买入”，并将其目标价从 20.00 美元提高至 52.00 美元。最后，高盛集团在 12 月 12 日的研究报告中将 uniQure 的目标价从 9.00 美元提高至 20.00 美元，并给予该股票 “中性” 评级。一位研究分析师对该股票给予了卖出评级，三位给予了持有评级，六位给予了买入评级，还有一位给予了强力买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 38.89 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on uniQure</strong></p>
<div class="lb-trans"><p><strong>获取我们对 uniQure 的最新股票分析</strong></p>
</div><h2>uniQure Price Performance</h2>
<div class="lb-trans"><h2>uniQure 价格表现</h2>
</div><p>The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market cap of $673.20 million, a P/E ratio of -2.50 and a beta of 0.36. The firm's fifty day moving average is $13.82 and its two-hundred day moving average is $10.69.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.92，速动比率为 6.51，流动比率为 6.51。该公司的市值为 6.732 亿美元，市盈率为-2.50，贝塔值为 0.36。该公司的 50 日移动平均线为 13.82 美元，200 日移动平均线为 10.69 美元。</p>
</div><h2>Insider Buying and Selling at uniQure</h2>
<div class="lb-trans"><h2>uniQure 的内部买卖</h2>
</div><p>In other news, CEO Matthew C. Kapusta sold 28,341 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now directly owns 651,454 shares of the company's stock, valued at $6,703,461.66. This represents a 4.17 % decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Christian Klemt sold 2,916 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares of the company's stock, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock valued at $961,401 in the last three months. 4.74% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 Matthew C. Kapusta 在 3 月 4 日的交易中出售了 28,341 股公司的股票。该股票以平均价格 10.29 美元出售，总交易额为 291,628.89 美元。出售后，首席执行官现在直接持有 651,454 股公司的股票，价值为 6,703,461.66 美元。这代表其持股减少了 4.17%。该交易在向证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，首席财务官 Christian Klemt 在 2 月 27 日的交易中出售了 2,916 股公司的股票。该股票以平均价格 11.32 美元出售，总交易额为 33,009.12 美元。交易完成后，首席财务官现在直接持有 155,168 股公司的股票，价值约为 1,756,501.76 美元。此交易代表其持股减少了 1.84%。该交易的披露信息可在此找到。在过去三个月中，内部人士共出售了 90,830 股公司股票，价值为 961,401 美元。当前 4.74% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On uniQure</h2>
<div class="lb-trans"><h2>对 uniQure 的对冲基金观点</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC purchased a new position in uniQure during the fourth quarter worth $38,410,000. Franklin Resources Inc. grew its holdings in uniQure by 33.1% during the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock valued at $35,103,000 after purchasing an additional 494,726 shares during the last quarter. Point72 Asset Management L.P. raised its position in uniQure by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock worth $31,282,000 after purchasing an additional 794,459 shares during the period. Integral Health Asset Management LLC lifted its stake in uniQure by 175.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock worth $19,426,000 after purchasing an additional 700,000 shares during the last quarter. Finally, RTW Investments LP boosted its position in shares of uniQure by 8,936.3% during the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock valued at $15,958,000 after buying an additional 893,625 shares during the period. Institutional investors own 78.83% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该公司的股票。Avoro Capital Advisors LLC 在第四季度购买了 uniQure 的新头寸，价值为 38,410,000 美元。Franklin Resources Inc.在第四季度将其在 uniQure 的持股增加了 33.1%。Franklin Resources Inc.现在持有 1,987,688 股生物技术公司的股票，价值为 35,103,000 美元，此前在上个季度又购买了 494,726 股。Point72 Asset Management L.P.在第四季度将其在 uniQure 的持股增加了 81.3%。Point72 Asset Management L.P.现在持有 1,771,352 股生物技术公司的股票，价值为 31,282,000 美元，此前在该期间又购买了 794,459 股。Integral Health Asset Management LLC 在第四季度将其在 uniQure 的持股增加了 175.0%。Integral Health Asset Management LLC 现在持有 1,100,000 股生物技术公司的股票，价值为 19,426,000 美元，此前在上个季度又购买了 700,000 股。最后，RTW Investments LP 在第四季度将其在 uniQure 的持股增加了 8,936.3%。RTW Investments LP 现在持有 903,625 股生物技术公司的股票，价值为 15,958,000 美元，此前在该期间又购买了 893,625 股。机构投资者持有该公司 78.83% 的股票。</p>
</div><h2>uniQure Company Profile</h2>
<div class="lb-trans"><h2>uniQure 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.</p>
<div class="lb-trans"><p>uniQure N.V.为患有罕见和其他严重疾病的患者开发治疗方案。它提供的 HEMGENIX 已完成针对 B 型血友病的 III 期 HOPE-B 关键试验。该公司还开发了 AMT-130，这是一种正在进行 I/II 期临床研究的基因治疗，用于治疗亨廷顿舞蹈症。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐阅读</h2>
</div><ul>
<li>Five stocks we like better than uniQure</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell</li>
<li>What is the Euro STOXX 50 Index?</li>
<li>Top 3 Beverage Stocks Pouring Out Profits</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>CarMax and Carvana: Steering the Used Car Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 uniQure</li>
<li>如何投资 FAANG 股票</li>
<li>便士股票激增，SurgePays 上涨 70%：买入的一个理由，卖出的五个理由</li>
<li>什么是欧元 STOXX 50 指数？</li>
<li>三大饮料股票带来丰厚利润</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>CarMax 和 Carvana：引领二手车市场</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in uniQure Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 uniQure 吗？</h2>
</div><p>Before you consider uniQure, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 uniQure 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而 uniQure 并不在名单上。</p>
</div><p>While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 uniQure 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

uniQure (NASDAQ:QURE) 股价下跌 4.2% - 原因如下